

Index

A

- Adenylate cyclase (AC), 39
- A kinase anchoring proteins (AKAPs), 41

B

- Basal cell carcinoma (BCC), 156
- Basal cell nevus syndrome (BCNS)
 - HH signaling, 153–154
 - medulloblastoma, 113, 115, 117
- Breast cancer
 - DCIS and IBC, 140
 - ductal hyperplasia and dysplasia, 141
 - Gorlin's syndrome, 139
 - immunohistochemistry, 140
 - mutation analysis, 139–140
 - PTCH1 protein, 140
 - therapeutic target
 - cyclopamine and CUR0199691, 142
 - hedgehog signaling modulators, 142–144
 - phase II trial, 145
 - phase I trial, 142, 145
 - plant-derived steroidal alkaloids, 142

C

- Cancer stem cells (CSCs), 152, 154
- Cancer treatment resistance
 - chemoradiotherapy (CRT), 152
 - growth factors (GFs), 152
 - HH signaling
 - anti-apoptosis and cell cycle regulation, 155
 - DNA damage, 155–156
 - Gorlin syndrome, 153–154
 - HH regulating therapeutics development, 157–158
 - IR-induced DSB, 153

- maintenance of homeostasis, 151
- MDR transporter system, 156–157
- Smo, 153
 - tumor regrowth and cancer stem cells, 154
 - hypoxia and molecular targeting agents, 153
 - P53 and apoptosis, 153
 - protumorigenic signaling cascade, 152–153
- Cerebellar granule precursors (CGPs), 110–112
- Cerebellum
 - atoh1* factor, 111
 - CGP, 111, 112
 - in situ hybridization, 111
 - neuron types, 110
 - shh signaling, 110–111
 - vitronectin, 111
- Ciliary Smo localization, 6
- Corn lily plant. *See Veratrum californicum*
- Costal2 (COS2) protein, 34–35
- Cyclopamine, 95–96, 157
 - clinical application, 206
 - congenital cyclopia, 187
 - discovery and development, IPI-926
 - acid lability, 197
 - chromatography, 200
 - deficiency, 200
 - in vitro and in vivo profiling, 199
 - semisynthetic analogs, D-ring, 197, 198
 - Veratrum californicum*, 199
 - Drosophila genetics, 189
 - drug properties, 192–193
 - hedgehog pathway, 187, 189
 - IPI-926 preclinical pharmacology
 - anti-tumor activity, 201
 - BODIPY-cyclopamine, 200
 - Gli1 and Ptc1, 200
 - Gli-1 expression inhibition, 200, 201
 - immunohistochemistry method, 203
 - medulloblastoma, 200–201

Cyclopamine (*cont.*)

pancreatic adenocarcinoma (PDA), 203
 pharmacokinetic and pharmacodynamic,
 203

medicinal chemistry (*see* Medicinal
 chemistry)

natural steroidal alkaloid, 189–190

synthetic chemistry, 190, 191

D

Decapentaplectic (Dpp), 28

Decapentapleigic (dpp) gene, 6

Dispatched (Disp) protein, 3

DNA damage, 155–156

Double strand breaks (DSBs), 153, 155

Ductal carcinomas in situ (DCIS), 140

E

Extracellular matrix (ECM), 22–23

F

Farnesyl transferase inhibitors (FTIs), 71

G

G α family, 37

Gli1 binding sites (GBS), 79

Gli1 expression, 81

Glioma-colonic polyposis syndrome. *See*
 Turcot's syndrome

Gli proteins, 52, 53, 58

Glycerophosphatidylinositol (GPI) motif, 23

Glycosaminoglycan (GAG) chains, 23, 24

Gorlin's syndrome. *See also* Basal cell nevus
 syndrome

breast cancer, 139

cancer treatment resistance, 153–154

Hh signaling

activation, cancers, 91

link, human cancer, 89–90

medulloblastomas mouse models, 93

small-molecule inhibitors, 166

smoothened signaling, G-protein effector
 network, 33

G protein-coupled receptor kinase 2 (GRK2),
 134

G-protein coupled receptors (GPCRs),

53–54, 133

carboxyl-terminal intracellular tail, 37

cysteine rich domain, 35–36

Frizzled (FZ) family, 35

rhodopsin, 35

transmembrane domains and intracellular
 loops, 36–37

G-protein regulated kinase 2 (GRK2), 37

G-protein signaling network

adenylate cyclase (AC), 39

coupled receptor kinases and arrestins, 40

Drosophila GRK2 (dGRK2), 40

G α and G γ subunits, 39

G-protein modulators, 39–40

ligand stimulation, 38–39

PKA, 40–41

Granule cell precursors. *See* Cerebellar
 granule precursors

Growth factors (GFs), 152

Guanine nucleotide exchange factor (GEF),
 66–67

H

Hedgehog and protein kinase C signaling
 conventional, novel and atypical PKC,
 77–78

crosstalk

development, 80

Drosophila Su(fu), 79

GBS (*see* Gli1 binding sites)

Gli proteins, 79

human cancer, 81

LIGHT2 cells, 79

PKC α /PKC δ , 80

stem cells, 81

MEK/ERK pathway, 82

PKC isoforms, human cancer, 78

Hedgehog morphogene gradient regulation

atypical biosynthesis, 18, 19

dilemma in motion, 22–23

flies to mice

ECM, 24

Hh-HSPG interaction, 25

proteoglycans, 25

Shf protein, 25

HSPGs, 23–24

lipid-modified Hh

cholesterol moiety, 20

HSPG, 21

Niemann-Pick C1 (NPC1), 22

sterol sensing domain (SSD), 21–22

multiple carriers

cytonemes, 28

Drosophila, 26

ECM proteins, 25

exosomes, 28

lipoprotein particles, 27

- micelles formation, 27
 - NVPs, 28
 - paracrine model, 28
 - shedases, 26
 - plasma membrane routing, 18, 20
 - Hedgehog secretion
 - apical lumen, 24
 - lipid, 20–22, 165
 - routing, 20
 - Hedgehog signaling pathway activation,
 - human cancer
 - BCCs and medulloblastomas, 89–90
 - cancer initiation, progression and metastasis, 91–92
 - Drosophila* segmentation, 85
 - drug dosages testing and optimization, 97
 - Gorlin syndrome, 91
 - Hh-mediated carcinogenesis, mouse models
 - BCC, 93
 - medulloblastomas, 93–94
 - organ sites, 94–95
 - Hh signaling link, 89, 90
 - Hh signaling model, mammalian cells, 85–86
 - PTC
 - Hh ligands reception, 87
 - Hh receptor, 85–86
 - negative feedback regulation, 89
 - signal transduction (*see* Signal transduction, hedgehog pathway)
 - small molecule modulators
 - Hh signaling modulators, 96–97
 - natural products, 95–96
 - synthetic Hh signaling antagonists, 95, 96
 - Hedgehog signal transduction. *See also* Signal transduction, hedgehog pathway
 - Gli protein degradation and processing, 7–8
 - HSPGs regulation, 3
 - lipid modification and multimerization, 3
 - mammalian Hh signaling, 9
 - multiple Hh-binding proteins, 4
 - Ptc inhibition, Smo catalytically, 4–5
 - Smo
 - G protein and Cos2/Kif7-Ci/Gli signaling complex, 6–7
 - signaling, G-protein effector network, 34–35
 - trafficking and conformation, 5–6
 - Sufu, 8
 - Heparan sulfate proteoglycans (HSPGs), 3
 - Hh-interacting protein (HIP)
 - cancer initiation, progression, and metastasis, 92
 - negative regulation, 87, 89
 - Homologous recombination (HR), 155
 - Hypoxia, 153
- I**
- Intraflagellar transport (IFT), 6, 132
 - Invasive breast cancer (IBC), 140
- J**
- Jervine, 189
- K**
- Kinases and phosphatases
 - Hh signal transduction, 56–57
 - intracellular components, differential phosphorylation
 - appendages development, 57
 - Gli proteins regulation, 58–59
 - Hh activity thresholds, 58
 - modulation, 58–59
 - ZPA, 57–58
 - non-conserved mechanism, kinases
 - regulation, 55–56
 - phosphorylation events
 - Cos2, 51
 - fused (Fu) pathway component, 50
 - Sufu, 51
 - protein phosphorylation, 49–50
 - Smo activation, Hh response
 - C-tail, conformational change, 54
 - GPCRs, 53
 - phosphorylation, 54
 - regulation, 55
 - Smo phosphorylation and cell surface
 - accumulation, 54–55
 - Wnt stimulation, 53–54
 - STPs and PTPs, 56
 - transcriptional factor, Ci/Gli, 51–53
- M**
- Mammalian Smo (mSmo), 6
 - Mammary gland development
 - alveolar development, 135
 - hedgehog network gene expression and function
 - Gli* family, transcription factor genes, 138
 - Gli2* mRNA, 138
 - heterozygosity, 137
 - Ihh* and *Dhh*, 135, 136
 - myoepithelial cells, 137

Mammary gland development (*cont.*)*Ptch2*, 138*Ptch1* mRNA, 136mammalian Hedgehog signaling,
131–132non-canonical Hedgehog network
functions, 132–134

primary cilia, 139

rudimentary ducts, 134–135

Medicinal chemistry

C5–C6 and C12–C13 double bonds, 194

cyclopamine and jervine, 194

dehydroepiandrosterone, 191, 197

jervine, 189

KAAD-cyclopamine, 195

prostate-specific antigen (PSA), 195

SAR, 194

teratogens, 194

Medulloblastoma

basal cell nevus syndrome, 115

biologic aspects

cytogenetic abnormality, 115

Notch signaling pathway, 116–117

risk stratification, 116

Turcot's syndrome, 116

unsupervised analysis, 116

WNT pathway, 116

biologic characteristics, 114

central PNET, 113

children, 113–114

craniospinal irradiation and chemotherapy,
114

definition, 113

diagnosis, 114

dysregulation, SHH signaling, 117–118

genesis, 118, 119

germline *p53* mutations, 119, 120

insulin-regulatory pathway, 120

IPI–926 preclinical pharmacology,
200–201

males, 113

MYC family genes, 119

MEK/ERK pathway, 82

Mesencephalic vesicles, 106

Multiple drug resistant (MDR) system,
156–157

N

Nodal vesicular particles (NVPs), 28

Notum protein, 24

O

Oxysterols, 4

P

Pancreatic adenocarcinoma (PDA), 203

Pancreatic cancer

anti-cancer therapeutics

cyclopamine, 72

drug resistance mechanism, 73

KRAS synthetic lethal agents

identification, 71

RAS, 70–71

resectable nonmetastatic

adenocarcinoma, 70

RNAi screens, 72

Gli transcription, 69–70

KRAS mutation, 68

PanINs, 65

PDA

KRAS signaling, 66–67

neoplasms, genetic level, 65–66

progression and maintenance, 68

phospho-MAPK and phospho-AKT levels,
68–69

xenograft and orthotopic mouse model, 68

Pancreatic ductal adenocarcinoma (PDA)

neoplasms, genetic level, 65–66

progression and maintenance, 68

Pancreatic intraepithelial neoplasia (PanINs)

development, 67

pancreatic epithelium, 68

PDA, 62

Patched (PTCH) family, 132

Patched (PTC)

Hh ligands reception, 87

Hh receptor, 85–86

negative feedback regulation, 89

Pediatric brain tumors

aberrant activation

dysregulation, SHH components, 120–121

genetic alteration of components, 112–113

medulloblastoma (*see*

Medulloblastoma)

metastases, 112

patient treatment, HH pathway inhibitors

acrocipitofemoral dysplasia, 122–123

compound's characteristics, 122

cyclopamine, 121

Gli family transcription factors, 123

HhAntag–691 (Genentech), 121–122

insulin regulatory pathway, 123

pharmacokinetics, 122

SHH signaling, CNS development

brain boundaries, 108

cell expansion, 107–108

cerebellum, 110–112

dorso-ventral polarity, 106–107

forebrain, 108, 109

- fundamental events, 106
 - midbrain and hindbrain, 109–110
 - primordial brain vesicles, 106
- Permeability-glycoprotein (P-gp), 156–157
- Pertussis toxin (PTX), 38
- Phosphatidylinositol-4 phosphate (PI4P), 4–5
- Pilocytic astrocytoma, 121
- Processing determinant domain (PDD), 7
- Prosencephalic vesicles, 106
- Protein kinase A (PKA), 40–41
- Protein phosphatase 4 (PP4), 56, 57
- Protein phosphatase 2A (PP2A), 56, 57
- Protein tyrosine phosphatases (PTPs), 56
- PTCHI
 - abnormal signaling pathway, 89
 - BCCs and medulloblastomas, 89–90
 - Hh ligand reception, 87
 - Hh signaling modulators, 96
 - Hh target gene expression, 92
 - receptor, 132–133
 - signaling link, human cancer, 89

- R**
- Rathke's pouch, 120
- Resistance-nodulation-division (RND), 4
- Rhombencephalic vesicles, 106

- S**
- Ser/Thr protein phosphatases (STPs), 56
- Shifted (Shf) protein, 25
- Signal transduction, hedgehog pathway
 - acyltransferase, Skinny Hedgehog, 86
 - cytoplasmic regulators, 88
 - Gli* transcription factors, 88
 - HhN, 86
 - Hh proteins, 86–87
 - HIP, 87, 89
 - intraflagellar transport (IFT), 87, 89
 - Kif3a* gene, 88
 - SMO signaling, 87
- Small-molecule inhibitors
 - binding of Ptc1, 165
 - cell proliferation and differentiation, 163
 - Gorlin's syndrome, 166
 - Hh target gene expression, 166–167
 - lipoproteins and heparin sulfate
 - proteoglycans, 165
 - pharmacological modulation, HH
 - signaling, 164–165
 - smoothened
 - antagonists, 172
 - cyclopamine, 167, 172
 - downstream, 178–180
 - genetic analysis, 174
 - genetic mutations, 167
 - inhibitors, 173, 174
 - IPI-926, 172
 - Shh-dependent ciliary accumulation, 173
 - target, Hp pathway inhibitors, 167–171
 - upstream, 174–178
 - TGFβ signaling, 166
 - tumor cells, 166
- Smoothened (Smo) protein, 133, 134
 - antagonists, 172
 - cyclopamine, 167, 172
 - downstream, 178–180
 - genetic analysis, 174
 - genetic mutations, 167
 - inhibitors, 173, 174
 - IPI-926, 172
 - Shh-dependent ciliary accumulation, 173
 - target, Hp pathway inhibitors, 167–171
 - upstream, 174–178
- Smoothened (Smo) signaling, G-protein effector network
 - Gorlin syndrome, 33
 - GPCR (*see* G-protein coupled receptor)
 - hedgehog signal transduction, 34–35
 - heterotrimeric G-proteins, 37–38
 - signaling network (*see* G-protein signaling network)
 - small-molecule modulators, 41–42
- Smoothened (SMO) transducer, 131, 132
- Sonic hedgehog (SHH), 37–38
- Structure-activity relationship (SAR), 194
- Suppressor of fused (Sufu) protein, 8, 51, 117–118

- T**
- Telencephalon, 108, 109
- Terminal end bud (TEB), 134, 135
- Transforming growth factor-β (TGFβ)
 - signaling, 166
- Turcot's syndrome, 116

- V**
- Veratrum californicum*
 - discovery and development, IPI-926, 199
 - drug properties, 192
 - steroidal alkaloids, 187
- Vismodegib, 157

- Z**
- Zinc finger transcription factors, 1
- Zone of polarizing activity (ZPA), 57–58